



Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial

Stefan H. Hohnloser^{1*}, A. John Camm², Riccardo Cappato³,
Hans-Christoph Diener⁴, Hein Heidbüchel⁵, Lluís Mont⁶, Carlos A. Morillo⁷,
Hans-Joachim Lanz⁸, Heiko Rauer⁸, Paul-Egbert Reimitz⁹, Rüdiger Smolnik⁸, and
Josef Kautzner¹⁰

¹Division of Clinical Electrophysiology, Department of Cardiology, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany; ²Department of Cardiology, Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's University of London, Blackshaw Road, London SW17 0QT, UK; ³Department of Cardiovascular Diseases, Arrhythmia and Electrophysiology Research Center, Humanitas Clinical and Research Center, Via A. Manzoni 56, Rozzano, Milan 20089, Italy; ⁴Medical Faculty, University Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany; ⁵Department of Cardiology, Antwerp University Hospital, University of Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium; ⁶Department of Cardiology, Cardiovascular CIBER, Hospital Clinic, University of Barcelona, Carrer de Villarroel 170, 08003 Barcelona, Spain; ⁷Division of Cardiology, Department of Cardiac Sciences, Libin Cardiovascular Institute, University of Calgary, 1403 29th Street NW, Calgary, Alberta T2N 2T9, Canada; ⁸Department of Global Medical Affairs, Daiichi Sankyo Europe GmbH, Zielstattstr. 48, 81379 München, Germany; ⁹Department of Biostatistics & Data Management, Daiichi Sankyo Europe GmbH, Zielstattstr. 48, 81379 München, Germany; and ¹⁰Department of Cardiology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic

Received 11 May 2020; editorial decision 13 June 2020; accepted after revision 19 June 2020

Aims

This *post hoc* analysis of ELIMINATE-AF evaluated requirements of unfractionated heparin (UFH) and procedure-related bleeding in atrial fibrillation (AF) patients undergoing ablation with uninterrupted edoxaban or vitamin K antagonist (VKA) therapy.

Methods and results

Patients were randomized 2:1 to once-daily edoxaban 60 mg (or dose-reduced 30 mg) or dose-adjusted VKA (target international normalized ratio: 2.0–3.0). Uninterrupted anticoagulation was mandated for 21–28 days' pre-ablation and 90 days' post-ablation. During ablation, UFH administration targeted an activated clotting time (ACT) of 300–400 s. Periprocedural bleeding was differentiated between procedure-related (bleeding at puncture site, cardiac tamponade) and unrelated events. Of 614 randomized patients, 553 received study drug and underwent catheter ablation (edoxaban $n = 375$; VKA $n = 178$). The median (Q1–Q3) time from last dose to ablation procedure was 14.8 (13.3–16.5) vs. 16.5 (14.8–19.5) h (edoxaban vs. VKA group, respectively). Mean ACT (SD) ≥ 300 s was observed in 52% edoxaban- vs. 76% VKA-treated patients, despite a higher mean (SD) UFH dose in the edoxaban vs. VKA group [14 261 (6397) IU vs. 11 473 (4300) IU; exploratory P -value < 0.0001]. In the edoxaban group, 13 patients (3.5%) had procedure-related bleeds of whom 9 had received an UFH dose above the median (13 000 IU). In the VKA arm, 7 patients (3.9%) had procedure-related bleeds of whom 3 had received an UFH dose above the median (10 225 IU).

Conclusion

The rate of procedure-related major/clinically relevant non-major bleeding did not differ between the treatment arms despite higher doses of UFH used with edoxaban vs. VKA to achieve a target ACT during AF ablation.

Keywords

Edoxaban • Non-vitamin K antagonist oral anticoagulants • Anticoagulant • Atrial fibrillation • Ablation • Periprocedural anticoagulation

*Corresponding authors. Tel: +49 61 7395 0260; fax: +49 69 6301 7017. E-mail address: hohnloser@em.uni-frankfurt.de

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

What's new?

- This *post hoc* analysis of ELIMINATE-AF showed that patients anticoagulated with edoxaban during atrial fibrillation ablation received a higher dose of unfractionated heparin (UFH) to achieve recommended level of activated clotting time (ACT) than those treated with vitamin K antagonist.
- Despite the higher UFH dose, the mean ACT was lower in patients treated with edoxaban.
- The number of patients with procedure-related major/clinically relevant non-major bleeding did not differ between the treatment arms despite higher doses of UFH used in combination with edoxaban.

Introduction

Catheter ablation of atrial fibrillation (AF) is the most frequently performed ablation procedure world-wide and constitutes an effective treatment modality. However, the procedure can entail serious complications, including stroke, transient ischaemic attack, and cardiac tamponade.¹ To minimize these complications, current guidelines recommend continuation of oral anticoagulation with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) during the procedure, maintaining effective anticoagulation.² Four randomized controlled trials compared uninterrupted VKA vs. uninterrupted NOAC therapy in patients undergoing AF ablation.^{3–6} Each of these trials demonstrated low rates of ischaemic and bleeding events in patients treated with uninterrupted NOAC therapy. These results have prompted the guideline recommendation to perform AF ablation without interruption of warfarin or NOAC therapy.² The guidelines also recommend systemic anticoagulation with unfractionated heparin (UFH) during the ablation procedure to achieve an activated clotting time (ACT) of >300 s to avoid procedure-related thromboembolic events.^{1,2} Recent observations indicate that in order to achieve this target, heparin requirements may differ in patients receiving different NOACs compared to VKA.^{7–11} While Calkins *et al.*¹⁰ demonstrated that the amount of UFH required in subjects treated with the factor II inhibitor dabigatran or warfarin was similar, mean UFH doses tended to be higher in patients receiving a factor Xa inhibitor.^{3,5}

This *post hoc* analysis of the ELIMINATE-AF trial evaluated the correlation between UFH doses and ACT in patients undergoing AF ablation on an uninterrupted edoxaban- or VKA-based anticoagulation regimen. Particularly, the relationship between UFH doses and periprocedural major or clinically relevant non-major (CRNM) bleeding events was evaluated in detail.

Methods

Study design

The design, methodology, and primary results of ELIMINATE-AF have been previously reported in detail.^{6,12} In brief, ELIMINATE-AF (ClinicalTrials.gov: NCT02942576) was a multinational, multicentre, randomized, open-label, parallel-group, blinded-endpoint evaluation (PROBE) study. The protocol was approved by the institutional review

board or independent ethics committee at each participating study centre. All patients provided written informed consent prior to enrolment. Adult patients (≥ 18 years of age) with documented non-valvular AF (paroxysmal, ≤ 7 days; persistent, > 7 days but ≤ 12 months; long-standing persistent, > 12 months) scheduled for their first or repeated catheter ablation for AF were eligible. Patients were randomized in a 2:1 ratio to receive edoxaban or VKA using a block randomization method. Patients randomized to edoxaban received once-daily edoxaban 60 mg (30 mg if they met 1 or more of the criteria for dose reduction).¹² The preferred VKA varied across countries (phenprocoumon in Germany and Belgium, acenocoumarol in Spain, and warfarin in Belgium and in all other countries). Patients randomized to a VKA were required to maintain an international normalized ratio of 2.0–3.0 at least for the last 10 days prior to ablation.

Uninterrupted anticoagulation was mandated for 21–28 days pre-ablation and continued for 90 days post-ablation. The maximum interval between the last pre-ablation edoxaban dose and the ablation procedure was 18 h in order to maintain sufficient inhibition of endogenous factor Xa. During ablation, UFH was used according to contemporary guideline recommendations^{1,2} targeting an ACT of 300–400 s. The first dose of UFH was given after sheath placement before or immediately after the transseptal puncture. For the duration of the ablation when catheters were in the left atrium, investigators were instructed to maintain an ACT ≥ 300 s by administering repeated boluses of UFH. Activated clotting time was assessed within 15 min after the administration of the bolus dose and regularly thereafter. Study medication was restarted at least 6 h post-sheath removal after achieving adequate haemostasis.

Parameters of coagulation were correlated with major or CRNM bleeding events (ISTH definition). For this purpose, only those events were considered which occurred from start of ablation up to 48 h after the end of the ablation procedure. Periprocedural bleeding was differentiated between procedure-related (bleeding at puncture side and cardiac tamponade) and unrelated events.

Statistical analysis

The administered heparin doses and ACT values in both treatment groups are presented descriptively. All *P*-values for group comparisons are exploratory.

Results

Patient population

A total of 632 patients were enrolled at 58 sites across 11 countries in Europe, Asia, and Canada. Of these, 614 patients were randomized, and 602 received at least one dose of study medication. A total of 553 subjects (375 in the edoxaban group and 178 in the VKA group) received study drug and underwent catheter ablation. The baseline characteristics of the two patient groups were well balanced (Table 1) and represented a typical AF ablation population with a male preponderance and a mean age of 60.5 years. The median (Q1–Q3) time interval between the last intake of study medication and start of the ablation procedure was 14.8 (13.3–16.5) h in the edoxaban group vs. 16.5 (14.8–19.5) h in the VKA group.

Heparin dosing and activated clotting time measurements

Data on UFH use on the day of ablation were collected in 552 patients, 374 assigned to edoxaban therapy and 178 assigned to

receive VKA. The median (Q1–Q3) UFH dose administered was higher in the edoxaban group than in the VKA group (Table 2). Heparin dosing tended to be lower in patients with a first ACT measurement of ≥ 300 vs. < 300 s for all patients (Table 2).

The median (Q1–Q3) ACT over the course of the ablation was lower in the edoxaban group than in the VKA group (Table 3; exploratory P -value < 0.0001). An individual mean ACT of ≥ 300 s over the

course of the procedure was achieved in 52% of patients in the edoxaban group vs. 76% in the VKA group. Median (Q1–Q3) heparin dosing was similar in patients with mean ACT measurement of < 300 vs. ≥ 300 s (Table 3). In the edoxaban treatment group, the first ACT was ≥ 300 s for 47% and in the VKA group for 66% of patients (exploratory $P < 0.0001$; Table 4).

Table 1 Patient characteristics

ITT analysis set	Total N = 614	Edoxaban N = 411	VKA N = 203
Age (years)	60.5 (53–67)	60.0 (53–67)	61.0 (52–67)
Male, n (%)	439 (71.5)	290 (70.6)	149 (73.4)
CHA ₂ DS ₂ -VASc score			
Mean (SD)	1.7 (1.5)	1.8 (1.6)	1.7 (1.4)
Median (Q1–Q3)	2.0 (1.0–3.0)	2.0 (1.0–3.0)	2.0 (1.0–2.0)
Medical history, n (%)			
Congestive heart failure	110 (17.9)	71 (17.3)	39 (19.2)
Previous CAD (prior MI, prior PCI, or prior CABG)	117 (19.2)	76 (18.6)	41 (20.3)
Previous MI	24 (3.9)	19 (4.6)	5 (2.5)
Previous stroke/TIA ^a	30 (4.9)	22 (5.4)	8 (3.9)
Peripheral artery disease	10 (1.6)	7 (1.7)	3 (1.5)
Diabetes mellitus	87 (14.2)	55 (13.4)	32 (15.8)
Hypertension	371 (60.4)	250 (60.8)	121 (59.6)
Mild valvular heart disease	52 (8.5)	32 (7.8)	20 (9.9)
AF type, n (%)			
Paroxysmal	415 (67.6)	284 (69.1)	131 (64.5)
Persistent	166 (27.0)	105 (25.5)	61 (30.0)
Long-standing persistent	33 (5.4)	22 (5.4)	11 (5.4)
Ablation population, mITT with ablation analysis set	N = 553	N = 375	N = 178
Last dose of IP to start of CA procedure (h)			
Median (Q1–Q3)	15.4 (13.5–17.1)	14.8 (13.3–16.5)	16.5 (14.8–19.5)
Sheath removal to next dose of IP (h)			
Median (Q1–Q3)	6.7 (6.1–8.0)	6.7 (6.1–8.0)	6.6 (6.1–7.9)
Type of CA performed, n (%)			
De novo CA	460 (83.2)	315 (84.0)	145 (81.5)
Re-do CA	93 (16.8)	60 (16.0)	33 (18.5)
CA technique used, n (%)			
Radiofrequency	368 (66.7)	247 (65.9)	121 (68.4)
Cryoballoon	181 (32.8)	127 (33.9)	54 (30.5)
Other	3 (0.5)	1 (0.3)	2 (1.1)
Percentage time in TTR (2.0–3.0) with VKA			
N			178
Mean (SD)			64.1 (21.1)
Median			64.8
Q1–Q3			48.3–82.1
Percentage time in TTR (1.8–3.2) with VKA			
N			178
Mean (SD)			80.9 (17.0)
Median			84.7
Q1–Q3			70.8–95.2

CA, catheter ablation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; IP, investigational product; ITT, intent to treat; mITT, modified intent to treat; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack; TTR, time in therapeutic range; VKA, vitamin K antagonist.

^aIncludes ischaemic, embolic, and undetermined; haemorrhagic stroke prohibited.

Table 2 Heparin dose requirements in patients with ACT <300 s vs. ≥300 s

Heparin dose (IU)	Total (N = 553)	Edoxaban (N = 375)	VKA (N = 178)
N	552	374	178
Mean (SD)	13 361.8 (5945.3)	14 260.9 (6397.2)	11 472.6 (4300.4)
Median	12 301	13 000	10 225
Q1–Q3	10 000–16 000	10 000–17 500	8541–14 000
First ACT			
<300 s			
N	256	195	61
Mean (SD)	14 679.6 (6510.8)	15 423.0 (6766.6)	12 303.2 (4957.6)
Median	14 000	14 250	12 000
Q1–Q3	10 000–18 000	11 000–18 000	9000–15 500
≥300 s			
N	292	176	116
Mean (SD)	12 264.4 (5136.7)	13 051.0 (5697.9)	11 070.0 (3869.7)
Median	11 000	12 500	10 000
Q1–Q3	9000–15 000	10 000–15 875	8520–13 000
Minimum ACT			
<300 s			
N	417	301	116
Mean (SD)	13 737.5 (6138.9)	14 515.9 (6445.5)	11 717.8 (4716.6)
Median	12 500	13 000	10 500
Q1–Q3	10 000–17 000	10 000–18 000	8400–15 000
≥300 s			
N	131	70	61
Mean (SD)	12 295.1 (5113.1)	13 361.5 (6073.5)	11 071.4 (3372.7)
Median	12 000	12 500	10 250
Q1–Q3	9000–14 500	10 000–15 750	9000–13 000
Maximum ACT			
<300 s			
N	50	43	7
Mean (SD)	12 265.2 (5131.7)	12 889.8 (5184.4)	8428.6 (2636.7)
Median	11 000	11 720	8000
Q1–Q3	10 000–15 000	10 000–16 000	8000–9000
≥300 s			
N	498	328	170
Mean (SD)	13 505.9 (6005.2)	14 482.7 (6510.2)	11 621.3 (4315.4)
Median	12 500	13 000	10 800
Q1–Q3	10 000–16 000	10 000–18 000	9000–14 000
Mean ACT			
<300 s			
N	219	177	42
Mean (SD)	13 833.8 (6432.1)	14 427.3 (6689.9)	11 332.7 (4463.9)
Median	12 500	13 000	10 000
Q1–Q3	10 000–16 331	10 000–17 000	8000–13 000
≥300 s			
N	329	194	135
Mean (SD)	13 099.0 (5574.7)	14 180.1 (6108.6)	11 545.5 (4266.4)
Median	12 000	13 000	10 600
Q1–Q3	10 000–16 000	10 000–17 500	9000–14 000

ACT, activated clotting time; IU, international units; SD, standard deviation.

Table 3 Overview of ACT

	Total (N = 553)	Edoxaban (N = 375)	VKA (N = 178)
Individual mean ACT (s)			
N	548	371	177
Mean (SD)	314.2 (51.4)	302.8 (41.6)	338.0 (61.2)
Median	307.7	301.4	332.6
Q1–Q3	281.6–341.5	277.0–330.4	300.5–371.0
Mean ACT categories, n (%)			
<300 s	219 (40.0)	177 (47.7)	42 (23.7)
≥300 s	329 (60.0)	194 (52.3)	135 (76.3)
Individual first ACT (s)			
N	548	371	177
Mean (SD)	307.3 (89.5)	293.9 (76.7)	335.2 (106.7)
Median	304.0	293.0	348.0
Q1–Q3	250.0–365.0	246.0–350.0	256.0–400.0
First ACT categories, n (%)			
<300 s	256 (46.7)	195 (52.6)	61 (34.5)
≥300 s	292 (53.3)	176 (47.4)	116 (65.5)
Individual minimum ACT (s)			
N	548	371	177
Mean (SD)	246.3 (75.8)	240.3 (65.3)	258.8 (93.0)
Median	240.0	240.0	246.0
Q1–Q3	182.0–296.5	187.0–284.0	179.0–320.0
Minimum ACT categories, n (%)			
<300 s	417 (76.1)	301 (81.1)	116 (65.5)
≥300 s	131 (23.9)	70 (18.9)	61 (34.5)
Individual maximum ACT (s)			
N	548	371	177
Mean (SD)	365.8 (65.2)	350.7 (53.7)	397.5 (75.2)
Median	361.0	351.0	390.0
Q1–Q3	328.5–395.0	317.0–376.0	357.0–426.0
Maximum ACT categories, n (%)			
<300 s	50 (9.1)	43 (11.6)	7 (4.0)
≥300 s	498 (90.9)	328 (88.4)	170 (96.0)

ACT, activated clotting time; SD, standard deviation.

Periprocedural anticoagulation and bleeding events

Between sheath insertion and up to 48 h after sheath removal, major, or CRNM bleeding events occurred in 17 (4.5%) edoxaban- compared with 7 (3.9%) VKA-treated patients (Table 5). In the edoxaban group, 11 of the 17 patients (65%) with bleeding events had received an UFH dose above the median (13 000 IU) while in the VKA arm, 3 of 7 patients (43%) with bleeding events had received an UFH dose above the median (10 225 IU) (Table 5). Procedure-related (bleeding at puncture site and cardiac tamponade) major or CRNM bleeding events occurred in 13 (3.5%) edoxaban- vs. 7 (3.9%) VKA-treated patients (Table 6). In the edoxaban group, 9 of 13 patients with procedure-related bleeds had received an UFH dose above the median (13 000 IU) while in the VKA arm, 3 of 7 patients with procedure-related bleedings received an UFH dose above the median (10 225 IU) (Figure 1).

Discussion

The present *post hoc* analysis of the ELIMINATE-AF trial shows that patients assigned to edoxaban during AF ablation procedure received a higher dose of UFH than those treated with VKA. Despite the higher administered UFH dose, the mean ACT was lower in the group of subjects treated with edoxaban. The number of patients with major or CRNM bleeding events related to the ablation procedure did not differ between the treatment arms despite higher doses of UFH used in combination with edoxaban. Of note, in the edoxaban group, 9 of 13 major or CRNM bleeding events occurred in patients who received an UFH dose above the median.

Our observations confirm those reported from other studies using uninterrupted factor Xa therapy around the time of AF ablation and extend these findings specifically to patients anticoagulated with edoxaban. For instance, in the VENTURE-AF study, the average total heparin dose used to manage ACT in patients undergoing catheter

Table 5 Major or CRNM bleeding events (ISTH) occurring from start of ablation up to 48 h after the end of the ablation procedure

	Total (N = 553), n (%)	Edoxaban (N = 375), n (%)	VKA (N = 178), n (%)
Major or CRNM bleeding (ISTH)	24 (4.3)	17 (4.5)	7 (3.9)
Heparin dose < median of treatment arm ^a		6	4
Heparin dose ≥ median of treatment arm ^a		11	3
Major bleeding (ISTH)	10 (1.8)	7 (1.9)	3 (1.7)
Heparin dose < median of treatment arm ^a		2	1
Heparin dose ≥ median of treatment arm ^a		5	2

CRNM, clinically relevant non-major bleeding; ISTH, International Society on Thrombosis and Haemostasis.

^aMedian heparin dose was 13 000 IU in edoxaban arm and 10 225 IU in VKA arm.

Table 6 Procedure-related major or CRNM bleeding events (ISTH) occurring from start of ablation up to 48 h after the end of the ablation procedure

	Total (N = 553), n (%)	Edoxaban (N = 375), n (%)	VKA (N = 178), n (%)
Major or CRNM bleeding (ISTH)	20 (3.6)	13 (3.5)	7 (3.9)
Heparin dose < median of treatment arm ^a		4	4
Heparin dose ≥ median of treatment arm ^a		9	3
Major bleeding (ISTH)	9 (1.6)	6 (1.6)	3 (1.7)
Heparin dose < median of treatment arm ^a		1	1
Heparin dose ≥ median of treatment arm ^a		5	2

CRNM, clinically relevant non-major bleeding; ISTH, International Society on Thrombosis and Haemostasis; IU, international units.

^aMedian heparin dose was 13 000 IU in edoxaban arm and 10 225 IU in VKA arm.




Figure 1 Procedure- and non-procedure-related major or CRNM bleeding events (ISTH) occurring from start of ablation up to 48 h after the end of the ablation procedure. CRNM, clinically relevant non-major; ISTH, International Society on Thrombosis and Haemostasis; VKA, vitamin K antagonist.

The reason for this difference in UFH requirements in patients' anticoagulated with different NOACs is not entirely clear.¹¹ A likely explanation could be that dabigatran, as a direct thrombin inhibitor, can prolong activated partial thromboplastin time (aPTT) and ACT in a dose-dependent manner, similar to VKAs.¹⁴ Factor Xa inhibitors, on the other hand, may affect ACT or aPTT to a lesser degree.¹¹ Our

observations are in line with other reports which also found shorter baseline ACT in patients on edoxaban therapy.¹⁵ This suggests that patients treated with edoxaban, rivaroxaban, or apixaban are expected to need higher doses of UFH to maintain ACT. It has therefore been speculated that use of ACT to reflect global intraprocedural anticoagulation is limited in the presence of uninterrupted NOAC therapy, particularly when using factor Xa inhibitors.¹¹

In almost all patients in the edoxaban arm, the time interval between the last edoxaban dose to septal puncture was <24 h, hence anticoagulation was truly uninterrupted (Table 4). The findings from this analysis attest to the safety of an uninterrupted NOAC strategy in patients undergoing AF ablation. Specifically, the low incidence of major or CRNM bleeding endpoints in the edoxaban group despite higher doses of UFH used, is reassuring.

The present analysis has some limitations. Among those is the relatively small sample size, residual bias due to the non-blinded nature of the study, and other inherent inadequacies of *post hoc* analyses. In addition, it is important to emphasize that the occurrence of vascular access bleeding after the ablation procedure may not depend only on anticoagulation drugs but also on multiple other factors such as the mode of puncture (e.g. ultrasound-guided vs. landmark-guided), sheath management after the procedure (e.g. immediate removal with Z stitch vs. delayed removal with compression) or the use of protamine.

Conclusions

The present analysis of the ELIMINATE-AF trial shows that considerably higher doses of UFH were needed with edoxaban vs. VKA to achieve a target ACT during AF ablation. Nevertheless, the number of patients with major or CRNM bleeding events related to the ablation procedure did not differ between treatments despite higher doses of UFH used in combination with edoxaban. However, in the edoxaban group, 9/13 major or CRNM bleeding events occurred in patients who received an UFH dose above the median. Careful post-operative surveillance appears to be indicated in patients in whom higher UFH doses had been administered during ablation.

Funding

This study was supported by Daiichi Sankyo Europe GmbH, Munich, Germany. Editorial support was provided by Shelley Narula from inScience Communications, Springer Healthcare Ltd, UK, and was funded by Daiichi Sankyo Europe GmbH, Munich, Germany in accordance with Good Publication Practice guidelines (<http://www.ismpp.org/gpp3>).

Conflict of interest: S.H.H. reports personal fees from Bayer Healthcare, BI, BMS, Daiichi Sankyo, Medtronic, Pfizer, SJM, and Zoll, outside the submitted work. J.C. has received personal fees for attending advisory committees and lecturing and his institution has received research grants from Daiichi Sankyo, and for work outside this project has received personal payments and institutional grants from Bayer, Boehringer Ingelheim, Pfizer/BMS, and Portola. R.C. reports research grants from and was a speaker consultant for Boston Scientific, Bayer, Medtronic, Abbott, St. Jude Medical, Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Biosense Webster, and Johnson & Johnson, during the conduct of this study. H.-C.D. received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from Abbott, Bayer Vital, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Pfizer, Portola, Sanofi-Aventis, and WebMD Global. Financial support for research projects was provided by Boehringer Ingelheim. H.C.D. received research grants from the German Research Council (DFG), German Ministry of Education and Research (BMBF), European Union, NIH, Bertelsmann Foundation, and Heinz-Nixdorf Foundation. H.C.D. served as editor of *Neurologie up2-date*, *Info Neurologie & Psychiatrie*, *Arzneimitteltherapie*, as co-editor of *Cephalalgia* and on the editorial board of *Lancet Neurology*. H.C.D. chairs the Treatment Guidelines Committee of the German Society of Neurology and contributed to the EHRA and ESC guidelines for the treatment of AF. H.H. has received no personal funding, and discloses institutional support as unconditional research grants from Medtronic, Daiichi Sankyo, Boehringer-Ingelheim, Bayer, Pfizer-BMS, Biotronik, Abbott and Bracco Imaging. Lluís Mont reports personal fees from Daiichi Sankyo. C.A.M. reports grants and personal fees from Bayer; personal fees from Pfizer and Servier; and was on a steering committee for Daiichi Sankyo during the conduct of this work. H.-J.L., H.R., P.-E.R., and R.S. are employees of Daiichi Sankyo Europe GmbH, Munich, Germany. J.K. reports personal fees and other from Daiichi Sankyo, during the conduct of the study; advisory boards, proctoring, and education events and received personal fees from Biosense Webster, personal fees from Boston Scientific; lectures, educational events and personal fees from Biotronik, advisory board, educational events, and personal fees from Medtronic, and advisory board and educational fees from Abbott (St.

Jude Medical), personal fees from Bayer, Boehringer Ingelheim and Pfizer outside the submitted work.

Data availability

De-identified individual participant data and applicable supporting clinical study documents are available on request, depending on circumstances, at <https://vivli.org>. In cases in which clinical study data and supporting documents are provided pursuant to the sponsor's policies and procedures, the sponsor will continue to protect the privacy of the clinical study participants. Details on data sharing criteria and the procedure for requesting access can be found at <https://vivli.org/oumember/daiichi-san-kyo/>.

References

- Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al.; TASK Force Members. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *Europace* 2012;**14**:528–606.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace* 2016;**18**:1609–78.
- Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. *Eur Heart J* 2015;**36**:1805–11.
- Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. *N Engl J Med* 2017;**376**:1627–36.
- Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. *Eur Heart J* 2018;**39**:2942–55.
- Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbuchel H, Mont L et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. *Eur Heart J* 2019;**40**:3013–21.
- Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M et al. Adequate initial heparin dosage for atrial fibrillation ablation in patients receiving non-vitamin K antagonist oral anticoagulants. *Clin Drug Investig* 2016;**36**:837–48.
- Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. *Circ Arrhythm Electrophysiol* 2013;**6**:460–6.
- Nagao T, Inden Y, Yanagisawa S, Kato H, Ishikawa S, Okumura S et al. Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. *Heart Rhythm* 2015;**12**:1972–8.
- Calkins H, Willems S, Verma A, Schilling R, Hohnloser SH, Okumura K et al. Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study. *Europace* 2019;**21**:879–85.
- Martin AC, Godier A, Narayanan K, Smadja DM, Marijon E. Management of intra-procedural anticoagulation in patients on non-vitamin K antagonist oral anticoagulants undergoing catheter ablation for atrial fibrillation: understanding the gaps in evidence. *Circulation* 2018;**138**:627–33.
- Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbuchel H, Lanz HJ et al. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: rationale and design of the ELIMINATE-AF study. *Clin Cardiol* 2018;**41**:440–9.
- Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. *Heart Rhythm* 2015;**12**:1162–8.
- van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wiene W, Feuring M et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. *Thromb Haemost* 2010;**103**:1116–27.
- Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M et al. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. *J Cardiovasc Electrophysiol* 2018;**29**:835–43.